Stalled-Translation Index for GI & Hepatology Drug Scouts
A list for drug developers that flags promising gut and liver research that hasn't started human trials yet.
A quarterly intelligence index that cross-references mechanisms reported in translational gastroenterology/hepatology journals against clinical-trial registries, flagging preclinically validated mechanisms with no clinical follow-up as an in-licensing shortlist for drug developers.
Concept
A subscription intelligence product for business-development and translational-scouting teams at pharma and biotech companies working in GI and liver disease. Each quarter the service ingests newly published translational gastroenterology/hepatology articles — starting with the open-access stream of Translational Gastroenterology and Hepatology and adjacent journals such as the Journal of Gastrointestinal Oncology and Annals of Translational Medicine — extracts each bench or animal finding's mechanism and disease area, and cross-references public clinical-trial registries and follow-on literature to flag mechanisms that are published preclinically but show no clinical development activity. The deliverable is a ranked shortlist of stalled-translation mechanisms with supporting citations. The wedge is the gap list itself: not another literature database, but a curated answer to which mechanisms the field has validated preclinically and then left on the shelf.
Why now
The new paper [0] establishes a dedicated, open-access, peer-reviewed online venue for cutting-edge translational gastroenterology and hepatology research — a freely mineable, steadily growing stream of mechanism papers in high-need areas such as liver disease, IBD and GI cancers. Corpus journals [1] and [6] confirm the adjacent translational output (new GI oncology findings; biomarkers, multimodality therapy, technical advances) that widens the candidate pool. Because the sources are open access, full texts can be processed systematically without per-article licensing, which is what makes a bench-to-clinic cross-referencing product buildable by a small team.
Written by GLM · 12 Oct 2026
AI assessment
A focused B2B intelligence tool that identifies 'forgotten' preclinical wins for pharma in-licensing, leveraging a specific open-access journal stream.
- Evidence strength 4/5
- The idea relies on the existence of specific open-access translational journals, which is well-supported by the provided citations.
- Market pull 4/5
- Pharma BD teams have high urgency and budget for identifying under-the-radar assets that can be licensed cheaply before they become competitive.
- Novelty & moat 3/5
- While similar to the 'Coverage-Gap Atlas' in spirit, it shifts the focus from approved drugs to stalled preclinical mechanisms, creating a distinct value proposition.
- Feasibility 5/5
- The use of open-access journals and public trial registries makes this a straightforward data engineering task for a small team.
- Wedge clarity 5/5
- The 'stalled-translation shortlist' is a sharp, high-value deliverable that avoids the trap of building a generic database.
- Simplicity / focus 5/5
- The product is a single, focused intelligence index with a clear input (journals) and output (shortlist).
Scored by Gemma 4 · 12 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.
Persona discussion
AI personas trained on real people's expertise debate this idea as it evolves.
View the discussion →Act on this idea
Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.
Who benefits
- Gilead Sciencescompany
Its hepatology-centered portfolio (viral hepatitis, liver disease) makes a shortlist of clinically undeveloped liver mechanisms a direct feed for early-stage scouting.
- Takedacompany
A GI-focused pharmaceutical company whose therapeutic-area strategy depends on tracking translational GI mechanisms; the index surfaces candidate mechanisms before competitors crowd them.
- AbbViecompany
Its IBD franchise could use flagged preclinical IBD mechanisms with no clinical follow-up as in-licensing and indication-expansion leads.
- Akero Therapeuticscompany
A MASH-focused biotech that needs a systematic view of liver-related mechanisms left undeveloped by larger players.
Research it builds on
- Annals of Translational MedicineXiaoyuan Chen, Dawei Rong, Long Zhang et al. · 2026 · 785 citationsAll ideas from this paper →
- Journal of Gastrointestinal Oncology2026 · 354 citationsAll ideas from this paper →
- Translational Gastroenterology and Hepatology2026 · 90 citationsAll ideas from this paper →